Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Kisqali is a prescription cyclin-dependent kinase 4 and 6 inhibitor containing ribociclib. Current labeling includes adjuvant treatment of selected hormone receptor-positive, HER2-negative stage II or III early breast cancer at high risk of recurrence and treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in adults.
read more about kisqali ...Ribociclib inhibits cyclin-dependent kinases 4 and 6. This reduces phosphorylation of retinoblastoma protein, arrests susceptible cells in the G1 phase of the cell cycle, and reduces proliferation.
Kisqali is used with an aromatase inhibitor for selected high-risk stage II or III early breast cancer. For advanced or metastatic disease, it is used with an aromatase inhibitor as initial endocrine-based therapy or with fulvestrant as initial endocrine-based therapy or after disease progression on endocrine therapy.
Early breast cancer uses 400 mg by mouth once daily for 21 consecutive days followed by seven days off treatment in each 28-day cycle, continued for three years or until recurrence or unacceptable toxicity. Advanced or metastatic breast cancer starts at 600 mg once daily for 21 days followed by seven days off in each cycle.
Serious concerns include interstitial lung disease or pneumonitis, severe cutaneous reactions, QT interval prolongation, liver toxicity, neutropenia, and fetal harm. Electrocardiograms, electrolytes, liver tests, and complete blood counts are checked during treatment. Tamoxifen use with Kisqali is avoided due to increased QT prolongation.
Kisqali treats selected hormone receptor-positive, HER2-negative early, advanced, or metastatic breast cancer under disease-specific criteria.
The recommended starting dose is 400 mg once daily for 21 days followed by seven days off.
The recommended starting dose is 600 mg once daily for 21 days followed by seven days off.
Current labeling uses treatment for three years or until disease recurrence or unacceptable toxicity.
DailyMed - KISQALI (ribociclib) tablet, film coated. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaeaef94-f3f5-4367-8ea2-b181d7be2da8. Date Accessed October 8, 2026.
KISQALI (ribociclib) Prescribing Information. Novartis. https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf. Date Accessed October 8, 2026.
Ribociclib. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a617008.html. Date Accessed October 8, 2026.
Ribociclib Succinate. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/ribociclib. Date Accessed October 8, 2026.
Ribociclib. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Ribociclib. Date Accessed October 8, 2026.